Exponent announces sale of BBI Group to Novo Holdings

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over £400 million.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents. Read more

Related Posts

Bangor will be abuzz with Maine science at annual festival

The Maine Science Festival’s headlining event will be a major collaboration with a local arts organization for the second year in...

23 March 2023

Report: National Institutes of Health added $264M to Maine economy in 2022

The National Institutes of Health supported 1,950 jobs and $264 million in economic activity in Maine during 2022 through $112.7 million in grants and...

22 March 2023

Northern Light completes deal to outsource diagnostics to Quest

Quest Diagnostics (NYSE: DGX), a Secaucus, N.J.-based diagnostic information services provider with a national footprint, said Monday that it has completed the acquisition...

21 March 2023